RayKnowChina Research Map
Shortlist0

Cancer

Hepatocellular carcinoma in Harbin

哈尔滨 肝细胞癌

All diseases in Harbin

4 hospitals in Harbin

Order: papers led on hepatocellular carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for hepatocellular carcinoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Harbin may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 57 papers led
    No open trial led
  2. 49 papers led
    No open trial led
  3. 31 papers led
    No open trial led
  4. 0 papers led

Hepatocellular carcinoma in every city Harbin on the disease page, with the national map

14

open trials on hepatocellular carcinoma with a hospital in Harbin

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with a listed hospital in Harbin as lead sponsor or study site. 1 of them are led by a hospital in Harbin. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  2. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  3. Recruiting
    Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
    Phase
    Phase 2/Phase 3
    Started
    2025-02
    Registry
    NCT06796803

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai

  4. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  5. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  7. Recruiting
    Phase 2 Study of WGI-0301 for Advanced HCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06309485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan

  8. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  9. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  10. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  11. Not yet recruiting
    Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07761286

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  12. Not yet recruiting
    JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07823348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  13. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

  14. Not yet recruiting
    A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06196775

    Age 18 years to 75 years (registered criteria)

    Led by Harbin Medical University HospitalHarbin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Harbin

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Harbin, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Haerbin MedicalUniversity哈尔滨医科大学附属肿瘤医院nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Heilongjiang University of Chinese Medicine黑龙江中医药大学附属第一医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Cancer Hospital, Harbin Medical University哈尔滨医科大学第三临床医学院nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth Affiliated Hospital of Harbin Medical University大庆市人民医院nonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliate Hospital, Harbin Medical University哈尔滨医科大学附属第一医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Clinical Hospital of Harbin Medical University哈尔滨医科大学附属第一医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第一医院nonenone31none02none1803142nonenonenonenonenone1nonenonenonenone2nonenonenonenonenone2none11nonenonenonenone1none2nonenonenonenonenonenone1nonenonenonenonenonenonenone
First Affiliated Hospital of Heilongjiang University of Chinese Medicine黑龙江中医药大学附属第一医院nonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone
First Clinical Hospital, Harbin Medical University哈尔滨医科大学附属第一医院nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fourth Affiliated Hospital of Harbin Medical University哈尔滨医科大学第四附属医院nonenonenone11none2none011nonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fourth Hospital Of Harbin Medical University哈尔滨医科大学第四附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Harbin First Hospital哈尔滨市第一医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Harbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院0125765nonenonenone21nonenone6nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Harbin Medical University Fourth Hospital哈尔滨医科大学附属第四医院nonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Harbin Medical University Hospital哈尔滨医科大学附属肿瘤医院nonenone01 open01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Harbin The First Hospital哈尔滨市第一医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Harbin University Cancer Hospital哈尔滨医科大学附属肿瘤医院nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Heilongjiang Province Hospital黑龙江省医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Heilongjiang Provincial Hospital黑龙江省医院nonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院nonenone4935nonenonenone1211none6nonenonenonenonenonenonenonenone1none8nonenonenonenonenone011none0none0nonenone1none3nonenonenonenonenone0nonenonenone1nonenonenonenone
Second Affiliated Hospital of Heilongjiang University of Chinese Medicine黑龙江中医药大学附属第二医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sixth Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第六医院nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tumor Hospital, Harbin Medical University哈尔滨医科大学附属肿瘤医院nonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Harbin.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for hepatocellular carcinoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Harbin on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data